Lab-Grown Neurons Reach a Milestone: How They Could Unlock Personalised Neurological Cures

The human brain contains roughly 86 billion neurons — cells so specialised and so architecturally complex that neurological diseases have resisted treatment longer than almost any other category of illness.

Alzheimer’s, Parkinson’s, ALS, and schizophrenia affect hundreds of millions of people, yet remain without cures. The reason is partly that the organ they damage is almost impossible to study directly.

Every other organ can be biopsied, imaged, or sampled with relative ease. The brain, locked inside the skull and intolerant of interference, has always guarded its secrets more closely than any other.

You cannot take a biopsy of a living brain the way you can a liver. You cannot watch neurons die in real time in a patient. Until recently, you could not test a drug on living human brain tissue in a dish.

That has now changed. Scientists can grow functioning human neurons in the laboratory — and in 2025, a landmark study produced over 400 distinct neuron types, the most comprehensive neuronal library ever assembled.

The implications reach far beyond the laboratory bench. They touch drug development, the prospect of repairing damaged brains, and even the ancient question of what it means for a piece of tissue to think or feel.

What Are Lab-Grown Neurons?

A neuron is a specialised cell that processes and transmits information through electrical and chemical signals. The brain contains hundreds of distinct subtypes, each with its own shape, electrical behaviour, and role.

A dopaminergic neuron in the substantia nigra — the type that degenerates in Parkinson’s disease — looks and behaves nothing like a pyramidal neuron in the cortex or a Purkinje cell in the cerebellum.

Lab-grown neurons are neurons produced from stem cells under laboratory conditions. The key starting material is human induced pluripotent stem cells, or iPSCs.

These are ordinary adult cells — usually from skin or blood — reprogrammed back to an embryonic-like state, capable of becoming almost any cell type in the body.

By exposing iPSCs to specific sequences of chemical signals — mimicking the cues that guide neuron formation in the embryo — scientists can coax them into becoming neurons of chosen types.

The result is a living human neuron, genetically identical to the donor. It fires electrical signals, forms synaptic connections, and responds to drugs as a real neuron would. Crucially, it can be grown from patients with specific diseases.

This means researchers can create neurons carrying the exact genetic profile of an Alzheimer’s patient, a Parkinson’s patient, or someone with a rare inherited condition — and study the disease in the very cell type it attacks.

The iPSC Revolution

The entire field rests on a discovery that stunned biologists. In 2006, the Japanese scientist Shinya Yamanaka showed that adult cells could be reprogrammed back into a stem-cell-like state.

By introducing just four genes, later dubbed the Yamanaka factors, he turned mature cells into induced pluripotent stem cells — capable of becoming any tissue in the body.

The implications were so profound that Yamanaka received the Nobel Prize in Physiology or Medicine in 2012, only six years later — an unusually fast recognition.

Before iPSCs, growing patient-specific human cells meant using embryonic stem cells, which raised serious ethical objections. Yamanaka’s method sidestepped that, using a patient’s own skin or blood.

This is why lab-grown neurons became possible at all. Every neuron in a modern disease study traces back to that 2006 breakthrough in cellular reprogramming.

How a Neuron Is Grown, Step by Step

Turning a skin cell into a working neuron is a carefully staged process, guided at every step by the signals a developing embryo would naturally provide.

First, a sample of the donor’s skin or blood cells is reprogrammed into iPSCs using the Yamanaka factors, resetting them to a blank, embryonic-like state.

Next, the iPSCs are bathed in precise sequences of signalling molecules. These tell the cells which region of the nervous system to become — forebrain, midbrain, spinal cord, and so on.

Over days and weeks, the cells mature. They sprout the long branching extensions — axons and dendrites — that let neurons connect, and begin firing electrical signals.

Getting the recipe right is the hard part. A slightly different signal at the wrong moment produces the wrong neuron, which is exactly why the ETH Zurich map of 400 recipes is so valuable.

The ETH Zurich Breakthrough: 400 Neuron Types

In 2025, a team at ETH Zurich led by Barbara Treutlein published a landmark study in the journal Science — the most comprehensive characterisation of human neuron diversity ever achieved in the laboratory.

The researchers combined iPSC reprogramming with carefully controlled exposure to morphogens — proteins that guide cell fate during development — to produce over 400 distinct neuronal subtypes.

They screened 480 morphogen combinations across roughly 700,000 cells, reading out each result with single-cell sequencing. It was an industrial-scale mapping of how to build any neuron on demand.

What makes this significant is not just the number. The library spans the full range of neuronal diversity — excitatory, inhibitory, motor, sensory, and the subtypes tied to specific brain regions and diseases.

Each type was catalogued by its gene expression, electrical properties, and shape, creating a reference map other laboratories can use to grow the exact neurons they need.

The practical impact is enormous. Drug developers testing a compound for Parkinson’s once relied on mice with artificially induced disease — models that often fail to predict human outcomes.

Now they can test on human dopaminergic neurons grown from Parkinson’s patients’ own cells. This dramatically improves preclinical testing, and may explain why so many drugs that succeed in animals later fail in people.

As Treutlein put it, the goal is to learn a “code” for building neurons — a set of rules linking developmental signals to cell identity that turns neuron production from guesswork into engineering.

Brain Organoids: Miniature Brains in a Dish

Alongside individual neuron cultures, researchers have developed a related technology: brain organoids — three-dimensional clusters of neurons that self-organise into structures resembling regions of the developing brain.

The technique was pioneered in 2013 by Madeline Lancaster and Jürgen Knoblich, who showed that stem cells could grow into “cerebral organoids” with distinct brain-like regions.

Brain organoids are not brains. They lack blood vessels, immune cells, sensory input, and the full architecture of a real brain. But they are far more than a flat layer of cells.

Organoids develop spontaneous electrical activity. They form layered structures resembling the cortex, and show gene-expression patterns matching specific stages of human brain development.

They have been used to model microcephaly, Zika virus infection, autism spectrum conditions, and early-stage Alzheimer’s — offering insights into developmental origins that animal models could not provide.

Can Neurons in a Dish Learn?

One experiment captured the public imagination more than any other. In 2022, the Australian company Cortical Labs reported a system they called DishBrain.

A layer of lab-grown neurons, connected to a computer, generated enough organised electrical activity to learn a simplified version of the video game Pong.

The neurons were not conscious or intentional. They simply responded adaptively to feedback signals in a way that demonstrated rudimentary learning — adjusting their firing to improve at the task.

The experiment drew enormous attention and helped launch a field some call “organoid intelligence,” which explores whether living neural tissue could perform computation.

It also raised profound ethical questions about the moral status of neural cultures — questions that remain actively debated. The parallels with artificial systems are explored in our article on neural networks, from the human brain to AI.

Separately, in 2023 researchers at Johns Hopkins University proposed a formal research roadmap for this area, coining the term “organoid intelligence” to describe the biological computing it might one day enable.

Whether living neurons will ever rival silicon for computing remains uncertain. But the experiments have already blurred a line we once thought firm — between a biological sample and a system that learns.

Fighting Parkinson’s and ALS

The diseases lab-grown neurons are best placed to tackle are those where access to the affected cell type has been the main bottleneck in research.

In Parkinson’s disease, the dopaminergic neurons of the substantia nigra progressively degenerate, for reasons still not fully understood.

Neurons grown from patients with familial Parkinson’s are now used to study how specific mutations cause cellular dysfunction, and to screen drugs that might slow the process.

Clinical trials of dopaminergic neuron transplantation — replacing lost neurons with lab-grown equivalents — are already underway in Europe and the United States.

In ALS, the motor neurons controlling voluntary movement degenerate. Lab-grown motor neurons from ALS patients have revealed cellular vulnerabilities invisible in animal models, pointing to new drug candidates now in trials.

Alzheimer’s and Psychiatric Conditions

In Alzheimer’s disease, the picture is more complex, involving multiple cell types and brain regions. But organoid models have shed new light on the disease’s cellular mechanics.

They have clarified the relationship between amyloid plaques, tau tangles, and neuronal death, and now serve as a platform for testing anti-amyloid therapies before they reach patients.

Beyond neurodegeneration, lab-grown neurons are illuminating psychiatric conditions such as schizophrenia and bipolar disorder — illnesses with strong genetic components but no clear pathology visible under a microscope.

By comparing neurons from patients and healthy controls, researchers are finding subtle differences in synaptic development, firing patterns, and gene expression that may underlie these conditions at the cellular level.

How genes are switched on and off in these cells is itself shaped by the environment, a process explored in our article on epigenetics.

Transplantation: Replacing Lost Neurons

Beyond studying disease, lab-grown neurons hold out a bolder promise: actually replacing the cells a disease has destroyed.

Parkinson’s is the leading test case. Because the disease kills one specific cell type — dopaminergic neurons — replacing them with healthy lab-grown equivalents is a natural strategy.

Early clinical trials are now transplanting stem-cell-derived dopamine neurons into patients’ brains, where the hope is that they will survive, connect, and restore lost function.

Using a patient’s own iPSCs offers a further advantage: cells that are genetically their own are far less likely to be rejected by the immune system.

If these trials succeed, they could shift neurology from managing symptoms to genuinely repairing the brain — a change as profound as any in modern medicine.

The Limits of the Technology

For all its promise, the technology has real limits that temper the excitement. Lab-grown neurons are powerful, but they are not the whole brain.

Organoids lack a blood supply, so they cannot grow beyond a few millimetres before their cores are starved of oxygen and nutrients. This caps their size and maturity.

They also mature slowly and often remain developmentally young, more like a fetal brain than an adult one — a limitation for studying late-onset diseases like Alzheimer’s.

And a dish of neurons, however sophisticated, lacks the sensory input, body, and lifetime of experience that shape a real brain. Researchers are working on vascularised organoids and faster maturation to close these gaps.

Some teams are grafting human organoids into animal hosts, which supply a blood supply and let the tissue mature further. These “chimeric” experiments are promising, but bring ethical complexities of their own.

Personalised Medicine and the Future of Neurology

One of the most transformative long-term applications is personalised medicine — testing treatments on a patient’s own cells before administering them to the patient.

Today, neurological treatment is largely trial and error. A neurologist prescribes a drug, waits to see if it works, adjusts the dose, and tries alternatives if it does not.

For conditions like epilepsy, resistance is common — up to 30% of patients do not respond adequately to available medications, and there is no way to predict who in advance.

Lab-grown neurons change this. A blood sample could be reprogrammed into iPSCs, turned into the relevant neuron type, and exposed to a panel of candidate drugs — revealing which works best for that patient before any is prescribed.

This is not science fiction; the technology exists. The barriers are practical — cost, processing time, standardised protocols — rather than scientific. As they fall, personalised neurology becomes a realistic near-term prospect.

The Consciousness Question

As organoids grow more sophisticated, an unavoidable question arises: could a cluster of human neurons ever develop something resembling experience?

Most scientists consider the risk extremely low for current organoids. They lack the scale, the sensory connections, and the organised architecture that consciousness appears to require in any living system.

But the honest answer is that we cannot be certain, because we do not yet understand what gives rise to consciousness even in a full human brain.

Without a theory of how subjective experience emerges from matter, we lack a clear test for when — if ever — a neural culture might cross a meaningful line. This deep problem is explored in our article on why science cannot yet explain consciousness.

The Ethical Landscape

Brain organoids and lab-grown neurons raise ethical questions the scientific community is actively working to address. The most pressing concerns the moral status of organoids.

As organoids incorporate more cell types and more sophisticated activity, the question of whether they could develop any form of experience becomes harder to dismiss entirely.

Several research groups have voluntarily imposed limits on organoid complexity and culture duration while governance frameworks catch up with the science.

Questions of consent and ownership also arise. iPSCs carry the complete genetic information of the donor, so neurons grown from them are, in a meaningful sense, the donor’s cells.

What rights do donors retain over research on those cells? Who owns discoveries made using them? These questions are being addressed through evolving consent frameworks, but they remain live issues. Similar dilemmas run through our article on gene editing in 2026.

Why This Matters

For decades, the brain’s inaccessibility made it the hardest organ to study and its diseases the hardest to treat. Lab-grown neurons remove that barrier for the first time.

Researchers can now hold a patient’s own neurons in a dish, watch their disease unfold, and test treatments directly on the affected cells — something impossible only a generation ago.

The 400-neuron library, the organoid revolution, and personalised drug testing together mark a genuine turning point for one of medicine’s most stubborn frontiers.

Progress will be gradual, and hype should be treated with caution. But the direction is unmistakable, and the pace of the last few years has surprised even the researchers driving it.

The same tools force us to confront profound questions about experience, identity, and the moral status of living tissue we can now build ourselves. The science of the brain is becoming, at last, a science we can hold in our hands.

For the millions living with conditions once deemed untreatable, that shift carries real hope. The path from a dish of neurons to a cure is long, but for the first time, it is a path we can actually see.

Frequently Asked Questions

Sources

• Takahashi, K. & Yamanaka, S. (2006). “Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors.” Cell, 126, 663 (DOI: 10.1016/j.cell.2006.07.024).
• Lin, HC., Janssens, J., et al. (Treutlein Lab, ETH Zurich) (2025). “Human neuron subtype programming through combinatorial patterning.” Science. Preprint: bioRxiv (DOI: 10.1101/2023.12.12.571318).
• Lancaster, M. A., Knoblich, J. A., et al. (2013). “Cerebral organoids model human brain development and microcephaly.” Nature, 501, 373 (DOI: 10.1038/nature12517).
• Kagan, B. J., et al. (2022). “In vitro neurons learn and exhibit sentience when embodied in a simulated game-world (DishBrain).” Neuron, 110, 3952 (DOI: 10.1016/j.neuron.2022.09.001).
• National Institute of Neurological Disorders and Stroke (NINDS).
• International Society for Stem Cell Research — Guidelines for Stem Cell Research.
• Web News For Us — The Human Microbiome.